Google says it received FDA clearance for the Pixel Watch 3's Loss of Pulse Detection feature, available in the EU and rolling out in the US at the end of March
Loss of Pulse Detection was announced last August as the Pixel Watch 3's latest safety feature, and it has finally been approved …
Context & Ripple Effects
Google had already been building Pixel Watch safety functions through a wider fall-detection rollout and later oxygen-saturation monitoring. Loss-of-pulse detection extends that device-sensor safety stack from detecting an incident to identifying a potentially critical physiological event.
The FDA decision matters because it removes the US regulatory barrier to availability, while the feature’s EU availability shows that launch timing can remain region-specific even for the same hardware.
First-order effects
- Pixel Watch 3 owners in the EU can use Loss of Pulse Detection, while US owners are slated to receive it at the end of March following FDA clearance.
- Google can position the Pixel Watch 3’s safety offering around an FDA-cleared function rather than solely its earlier consumer health and safety tools.
Second-order effects
- Competing smartwatch makers face a higher bar for matching emergency health features in the US when those features require regulatory clearance before rollout.
- Regional approval processes can make health-feature availability—not just sensor hardware—a differentiator in smartwatch purchase decisions.
Third-order effects
- Wearable competition is shifting toward sensor-driven safety features whose commercial reach depends on validation and regulatory pathways as much as software deployment.
- If this pattern continues, smartwatch platforms may increasingly ship common hardware globally but activate higher-stakes health functions market by market.
The trend: Consumer wearables are becoming regulated safety platforms, with sensor capabilities increasingly gated by local health approvals.